Pomezia’s company: “If the tests are positive, the first doses of the vaccine to Italy in November”

ROME – “The first 2-3 million doses of the Covid Oxford-Irbm-AstraZeneca vaccine should arrive in Italy by the end of November if the ongoing trial progresses positively, after temporary suspension due to a suspicious reaction in a volunteer then resulted not be related to the candidate vaccine. ” This was stated to Ansa Piero di Lorenzo, president of the Irbm of Pomezia, who collaborated with the Jenner Institute of Oxord University in the development of the vaccine prototype. If there are no critical issues and experimentation will continue as planned, “the schedule already announced by the Minister of Health, Roberto Speranza, will be respected.”

“We are working on a major European agreement for the Covid vaccine, the testing of which continues.” This was stated by Chancellor Luigi Di Maio speaking in Benevento at a meeting with voters together with the presidential candidate for the regional Valeria Ciarambino. “I applaud – added the head of the Farnesina – for the other countries that are locked up, because they are the countries of the tourists who come here to Italy.”

rep

Deepening

Expert alarm: “The virus also attacks the brain”

by our correspondent FABIO TONACCI

The vaccine experimentation was resumed after the temporary suspension due to a true reaction of one of the 50 thousand volunteers participating in the tests. The volunteer suffered from spinal inflammation, acute transverse myelitis, which consists of inflammation in one or more adjacent segments of the spinal cord. However, the independent expert panel that examined the matter established within days that this reaction was not related to the inoculation of the candidate vaccine.
This experiment, explains di Lorenzo, “is actually carried out in double blindness: this means that neither the doctors nor the patients know which of the volunteers is given the candidate vaccine and which only placebo. Therefore, he concludes, the reaction Suspicious could also occurred in a volunteer who had taken the placebo and not the drug. “